This morning, Nuvelo announced positive results from the Phase 1 trial of recombinant, secreted protein, NU206, the company’s lead compound from its Wnt Therapeutics Program. The single-center, double-blind, placebo-controlled, single-ascending dose (SAD) trial involved 32 healthy male volunteers. According to the press release, NU206 caused no serious adverse side effects and pharmacokinetics were predictable.
Dr. Ted W. Love, chairman and CEO of Nuvelo, stated, “Based on preclinical studies, we believe that NU206 promotes cell growth and repair, and, based also on results from this Phase 1 trial, believe it has the potential to offer a novel approach for the treatment of serious medical conditions such as gastrointestinal (GI) injury, inflammatory bowel disease, and bone disease.”
He added, “Because Nuvelo is in the process of merging with ARCA biopharma to create a cardiovascular-focused company, we are currently evaluating partnership and out-licensing opportunities for NU206 to continue development of the compound.”
NU206 is a recombinant, secreted protein designed to act as a key regulator of the Wnt pathway. This pathway is critical to the stimulation of cell growth and differentiation during homeostasis and pathogenesis in specific tissues, including the GI epithelium and bone.
Disclaimer.
